NewsCoronavirus

Actions

Froedtert enrolls first patient in Remdesivir trial to treat COVID-19

Posted
and last updated

Froedtert has enrolled its first patient in a new breakthrough trial of an antiviral drug to fight the coronavirus.

Remdesivir has been praised by top health officials as a way to treat COVID-19 patients, including from Director of the National Institute of Allergy and Infectious Diseases Dr. Anthony Fauci.

"What it has proven is that a drug can block this virus," Dr. Fauci said in late April. "The data shows that Remdesivir has a clear-cut significant positive effect in diminishing the time to recovery."

Froedtert Hospital in Wauwatosa is a part of a program with Gilead Sciences, the drug's manufacturer.

On Thursday, a hospital spokesperson said it has enrolled its first patient into the program.

The hospital will only be able to provide the drug to 10 patients who are on ventilators and have a certain level of kidney and liver function.

Report a typo or error // Submit a news tip

Coronavirus in Wisconsin

More data on Wisconsin's vaccination progress here.

Find a vaccination site here.

Check out county-by-county coronavirus case numbers here.

More information: COVID-19 on the Wisconsin DHS website

Latest news and headlines here.